Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SIGA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.22
+1225%
0.45
vs -0.04
Q4.22
N/A
-0.01
vs 0.98
Q1.23
N/A
-0.01
vs -0.01
Q2.23
N/A
-0.04
vs 0.03
Q3.23
N/A
-0.01
vs 0.45
Q4.23
+10200%
1.01
vs -0.01
Q1.24
+1500%
0.14
vs -0.01
Q2.24
+175%
0.03
vs -0.04
Q3.24
+300%
0.02
vs -0.01
Q4.24
-38%
0.63
vs 1.01
Sales Growth
YoY
Current
Estimates
Q3.22
+1390%
72.2M vs 4.8M
Q4.22
-90%
11.4M vs 115.4M
Q1.23
-21%
8.3M vs 10.5M
Q2.23
-65%
5.9M vs 16.7M
Q3.23
-87%
9.2M vs 72.2M
Q4.23
+926%
116.5M vs 11.4M
Q1.24
+206%
25.4M vs 8.3M
Q2.24
+271%
21.8M vs 5.9M
Q3.24
+8%
10M vs 9.2M
Q4.24
-30%
81.5M vs 116.5M
Return on Equity
QoQ
Q1.23
-1%
-0.01
vs -0.00
Q2.23
-2%
-0.02
vs -0.01
Q3.23
0%
-0.00
vs -0.02
Q4.23
+37%
0.37
vs -0.00
Q1.24
+6%
0.06
vs 0.37
Q2.24
+1%
0.01
vs 0.06
Q3.24
+1%
0.01
vs 0.01
Q4.24
+21%
0.21
vs 0.01
Institutionnal Ownership
QoQ
Q1.23
145
145
vs 164
-12%
Q2.23
135
135
vs 145
-7%
Q3.23
133
133
vs 135
-1%
Q4.23
140
140
vs 133
5%
Q1.24
149
149
vs 140
6%
Q2.24
159
159
vs 149
7%
Q3.24
178
178
vs 159
12%
Q4.24
179
179
vs 178
1%
globenewswire.com
7 hours ago
globenewswire.com
16 hours ago
zacks.com
18 hours ago
zacks.com
18 hours ago
seekingalpha.com
19 hours ago
Forecast
49%2025-Revenue
5%2025-EPS
23%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
NASDAQ
0.19 ( 3.62%)
Relative Strenght
19
Volume Buzz
-3%
Earning Acce
No
Dist 52w H.
58%Relative Strength
SIGA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SIGA compares to sector?